Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-02-09 DOI:10.1016/j.tranon.2025.102279

Ruiqing Ma , Guojun Li , Yingjiang Ye , Lei Liang , Chong Wang , Haipeng Zhou , Pu Zhang , Lubiao An , Guanjun Shi , Qian Chen , Hongbin Xu , Zhidong Gao

{"title":"Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei","authors":"Ruiqing Ma , Guojun Li , Yingjiang Ye , Lei Liang , Chong Wang , Haipeng Zhou , Pu Zhang , Lubiao An , Guanjun Shi , Qian Chen , Hongbin Xu , Zhidong Gao","doi":"10.1016/j.tranon.2025.102279","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Pseudomyxoma Peritonei (PMP) is an extremely rare disease characterized by progressive accumulation of mucinous ascites and implants in the peritoneum. We investigated the prognostic value for response to cytoreductive surgery (CRS) or hyperthermic intraperitoneal chemotherapy (HIPEC) and dissected potential beneficial targeted therapy utilizing genomic characteristics.</div></div><div><h3>Methods</h3><div>Whole-exome sequencing (WES) was performed on tissue specimens and matched white blood cells from 81 patients with PMP. The study investigated mutational signatures, profiling, and their correlation with progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>Signature 3 (HRD) and signature 15 (dMMR) were dominant. NMF cluster 1, characterized by signature 4, exhibited a worse prognosis. The p53 and TGF-β signaling pathways may contribute as risk factors for worse OS and PFS, respectively. <em>MUC16</em>-mutated patients had worse PFS (<em>P</em> = 0.016) and OS (<em>P</em> = 0.004) compared to wild-type patients. Patients with tumor mutational burden (TMB) > 1(<em>P</em> = 0.026) or alterations in <em>TP53</em> (<em>P</em> = 0.006) or <em>SMAD4</em> (<em>P</em> = 0.013) had significantly worse OS compared to those with a TMB < 1 or normal genes. Patients with homologous recombination deficiency (HRD) positivity (<em>P</em> = 0.003) or alterations in <em>TGFBR2</em> (<em>P</em> = 0.037) experienced worse PFS compared to their respective control groups. Furthermore, NMF cluster1 (<em>P</em> = 0.020), <em>TP53</em> (<em>P</em> = 0.004), and <em>MUC16</em> (<em>P</em> = 0.013) were identified as independent prognostic factors for OS, while HRD status (<em>P</em> = 0.003) was independent predictors for PFS in PMP.</div></div><div><h3>Conclusions</h3><div>The study reveals that genomic profiling can serve as a robust tool for identifying prognostic markers in PMP. The identified genomic mutations and signaling pathway offer new avenues for targeted therapies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"53 ","pages":"Article 102279"},"PeriodicalIF":5.0000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325000105","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Pseudomyxoma Peritonei (PMP) is an extremely rare disease characterized by progressive accumulation of mucinous ascites and implants in the peritoneum. We investigated the prognostic value for response to cytoreductive surgery (CRS) or hyperthermic intraperitoneal chemotherapy (HIPEC) and dissected potential beneficial targeted therapy utilizing genomic characteristics.

Methods

Whole-exome sequencing (WES) was performed on tissue specimens and matched white blood cells from 81 patients with PMP. The study investigated mutational signatures, profiling, and their correlation with progression-free survival (PFS) and overall survival (OS).

Results

Signature 3 (HRD) and signature 15 (dMMR) were dominant. NMF cluster 1, characterized by signature 4, exhibited a worse prognosis. The p53 and TGF-β signaling pathways may contribute as risk factors for worse OS and PFS, respectively. MUC16-mutated patients had worse PFS (P = 0.016) and OS (P = 0.004) compared to wild-type patients. Patients with tumor mutational burden (TMB) > 1(P = 0.026) or alterations in TP53 (P = 0.006) or SMAD4 (P = 0.013) had significantly worse OS compared to those with a TMB < 1 or normal genes. Patients with homologous recombination deficiency (HRD) positivity (P = 0.003) or alterations in TGFBR2 (P = 0.037) experienced worse PFS compared to their respective control groups. Furthermore, NMF cluster1 (P = 0.020), TP53 (P = 0.004), and MUC16 (P = 0.013) were identified as independent prognostic factors for OS, while HRD status (P = 0.003) was independent predictors for PFS in PMP.

Conclusions

The study reveals that genomic profiling can serve as a robust tool for identifying prognostic markers in PMP. The identified genomic mutations and signaling pathway offer new avenues for targeted therapies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.